Vismodegib
Brand name: Erivedge
Rank #446 of 500 drugs by total cost
$17.4M
Total Cost
1,317
Total Claims
$17.4M
Total Cost
87
Prescribers
$13K
Cost per Claim
0
Beneficiaries
1,332
30-Day Fills
$200K
Avg Cost/Provider
15
Avg Claims/Provider
About Vismodegib
Vismodegib (sold as Erivedge) was prescribed 1,317 times by 87 Medicare Part D providers in 2023, costing the program $17.4M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 443 | Encorafenib (Braftovi) | $17.6M | 1,209 |
| 444 | Cladribine (Mavenclad) | $17.5M | 228 |
| 445 | Enalapril Maleate (Enalapril Maleate) | $17.5M | 673,317 |
| 446 | Vismodegib (Erivedge) | $17.4M | 1,317 |
| 447 | Anastrozole (Anastrozole) | $17.4M | 626,025 |
| 448 | Naproxen (Naproxen) | $17.4M | 903,928 |
| 449 | Vedolizumab (Entyvio) | $17.4M | 2,034 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology